Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Jaromer

12 clinical trials in Jaromer, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Jaromer at a glance
12
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

12 trials in Jaromer

Open in trial search

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:PF-07328948
  • Sponsor:Pfizer Inc.

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Heart failure with reduced ejection fraction

Not yet recruiting

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Heart failure with reduced ejection fraction

Not recruiting

Study on JTT-861 for Patients with Heart Failure with Reduced Ejection Fraction

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:JTT-861 monohydrochloride dihydrate
  • Sponsor:Akros Pharma Inc.

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Eli Lilly & Co.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Jaromer

What the registry says about research in the country

01 Cardiovascular Research

Innovative research focusing on heart failure prevention and treatment, with particular emphasis on combination therapies to reduce cardiovascular events and mortality.

  • Heart Failure Prevention
  • Cardiovascular Death Risk Reduction
  • Combined Therapeutic Approaches

Studies examining novel drug combinations to enhance treatment outcomes in cardiovascular patients.

02 Cardiorenal Studies

Comprehensive research investigating the relationship between heart failure and kidney function, evaluating new therapeutic combinations for patients with dual conditions.

  • Chronic Heart Failure
  • Kidney Function Impairment
  • Cardiovascular Events

Focused on improving outcomes for patients with both cardiac and renal complications.

03 Metabolic Disorders

Advanced clinical research addressing type 2 diabetes and obesity, with emphasis on cardiovascular risk management in patients with multiple metabolic conditions.

  • Type 2 Diabetes Management
  • Obesity Treatment
  • Cardiovascular Risk Reduction

Evaluating new therapeutic options for complex metabolic disorders with cardiovascular implications.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.